Satiation peptides for weight loss and altered taste sensitivity

Abstract

The present application provides methods and compositions for AAV-mediated delivery of PYY and Glucagon-like Peptide 1 or an analog thereof (e.g., Exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of Ex-4 and PYY peptides also are provided. Methods and compositions are useful to promote weight loss and/or altered lipid taste sensitivity, as well as for the treatment of diabetes.

1 - 24 . (canceled) 
     
     
         25 . A method of inducing satiation in a subject comprising administering to the subject PYY and GLP-1 or an analog thereof, wherein the PYY is formulated as an orally disintegrating tablet that is topically administered to a tongue of the subject. 
     
     
         26 . The method of  claim 25 , wherein the PYY is PYY 3-36  comprising the sequence of SEQ ID NO: 2. 
     
     
         27 . The method of  claim 25 , wherein the GLP-1 analog is Exendin-4 comprising the sequence of SEQ ID NO: 10. 
     
     
         28 . The method of  claim 25 , wherein the PYY and the GLP-1 or analog thereof are administered separately. 
     
     
         29 . The method of  claim 28 , wherein the PYY is administered first, and the GLP-1 or analog thereof is administered second. 
     
     
         30 . The method of  claim 28 , wherein the GLP-1 or analog thereof is administered first and the PYY is administered second. 
     
     
         31 . The method of  claim 25 , wherein the PYY and GLP-1 or analog thereof are administered together. 
     
     
         32 . The method of  claim 25 , wherein the GLP-1 or analog thereof is formulated as an orally disintegrating tablet. 
     
     
         33 . The method of  claim 25 , wherein the GLP-1 or analog thereof is injected into the subject. 
     
     
         34 . The method of  claim 25 , wherein the method does not substantially increase a plasma concentration of PYY or GLP-1 or analog thereof in the subject. 
     
     
         35 . The method of  claim 31 , wherein the administering is performed between 30 and 120 minutes prior to eating.